Today was quiet. Compass Pathways, one of the biggest companies testing psilocybin — the active ingredient in magic mushrooms — as a treatment for depression, saw its stock tick up about 1.9%. But there was no news behind that bump. No breakthrough, no test results, no announcement. It's the kind of small move that usually fades within a couple of weeks, driven by everyday traders rather than any real change. The other big players — atai, Numinus, MindMed — barely moved at all. Beneath the surface, the real story is what these companies are waiting for: results from major trials still to come, including studies looking at whether psychedelics can help with obsessive-compulsive disorder and chronic pain.
Here is the deeper current. There is a quiet tug-of-war happening in this field between speed and proof. Some researchers are eager to test psychedelics against more and more conditions. Others warn that we still don't fully understand how these drugs actually work in the brain. One study being watched closely uses brain scans to see whether psychedelics really do rebuild connections between brain cells — but the likely outcome is messy. The scans may show real changes, yet those changes may not line up neatly with patients actually feeling better. That gap is not a failure. It's the field growing up. Real medicine is rarely a clean story, and the treatments that survive honest testing are the ones patients will one day be able to trust. Meanwhile, momentum is building on another front: with veterans' mental health back in the headlines, there's a real chance that lawmakers introduce a proposal in the coming weeks to open access to ibogaine — a plant-based psychedelic showing promise for opioid addiction and trauma — pointing to research from Stanford University.
For the people at the center of all this, the quiet is hard. A veteran carrying trauma that ordinary pills haven't touched doesn't feel comforted by "we're being careful." A person with severe obsessive-compulsive disorder, who has tried everything, reads about a psilocybin study and wonders if the answer will come in time for them. The waiting is its own kind of weight. But there's something worth holding onto here: the careful path is the one that protects them. A treatment rushed to market and later found unsafe would set everyone back years and break the trust that's been slowly built. The best possible outcome — the one genuinely within reach — is that these therapies arrive proven, safe, and covered by insurance, so that access isn't a lottery but a right. That's what today's patience is quietly buying.
The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first.
The intelligence that created you is still creating.
70%
COMPASS stock stays flat until big trial results arrive
Shares of COMPASS Pathways (ticker: CMPS), a company developing a synthetic psilocybin pill called COMP360, recently jumped about 2% for no clear reason. That small gain will likely disappear within three weeks, and the stock will drift sideways — up or down no more than 12% — until the company releases results from its large Phase 3 trial (the final, decisive round of human testing required before a drug can be approved). Nothing meaningful has changed about the company; the price move was just random market noise.
→ COMPASS stock will likely drift sideways until the company releases major clinical trial results — the recent small price jump means nothing.
Resolves: 2026-08-25 · Global
MARKETS
the precise call ▾
CMPS trades within a ±12% band through September absent a named Phase 3 readout; the 1.9% pop fully mean-reverts within 15 trading days.. No catalyst underlies today's move. Retail-driven noise reverts. Institutional capital waits for COMPASS COMP360 pivotal data, not headlines.
68%
US drug regulators won't publish new psychedelic rules before late 2026
The FDA (the US drug regulator) published a draft guidance document in 2023 explaining how companies should design clinical trials for psychedelic drugs. As of now, the FDA has not replaced or updated that document, and it almost certainly won't release a new one before the final quarter of 2026. That 2023 draft remains the rulebook any company — including Lykos Therapeutics, which is trying to resubmit its MDMA-assisted therapy application after the FDA rejected it — must follow when designing their studies.
→ The FDA's 2023 draft document is still the only official guide for psychedelic drug trials, and that won't change before the end of 2026.
Resolves: 2026-10-31 · USA
REGULATORY
the precise call ▾
FDA issues no new psychedelic-specific guidance document before Q4 2026; existing 2023 draft remains the operative framework for any Lykos resubmission.. Guidance revision requires interagency review cycles that outlast this quarter. Sponsors will lean on functional-unblinding critiques already documented.
62%
Brain scan study shows drug effect but can't link it to patient improvement
A study called SYNVEST is using advanced brain imaging to look at whether psychedelics actually change the density of connections between brain cells by acting on a specific receptor called 5-HT2A (a docking point on brain cells that psychedelics latch onto). The scans will likely show that yes, something measurable changes in the brain. But researchers won't be able to clearly show that more brain-connection changes equals more symptom relief in patients — which is the headline the field was hoping to prove.
→ The study will confirm psychedelics change the brain, but won't prove those brain changes are what makes people feel better.
Resolves: 2026-10-28 · Global
RESEARCH
the precise call ▾
SYNVEST imaging shows real 5-HT2A synaptic effects but no clean clinical correlation, disappointing simple neuroplasticity narratives.. Consensus of 2 agents: neuroscientist, fda_reviewer. 1 dissenting.
62%
Brain scan study shows drug effect but can't link it to patient improvement
SYNVEST researchers will use PET scans (a type of brain imaging that measures biological activity) to look for changes in synaptic density — essentially, how many connection points exist between brain cells — after people take psychedelics. The scans will very likely show real, measurable changes tied to how psychedelics interact with 5-HT2A receptors (specific docking sites on brain cells). But those brain changes won't line up neatly with who feels better or worse, which pokes a hole in the popular idea that 'more brain rewiring equals more healing.'
→ The study will prove psychedelics change the brain in measurable ways, but won't be able to show those changes are what causes people to get better.
Resolves: 2026-12-15 · Global
RESEARCH
the precise call ▾
SYNVEST shows measurable 5-HT2A-linked synaptic density changes but WITHOUT clean dose-response correlation to clinical improvement, complicating the neuroplasticity narrative.. PET synaptic imaging reliably detects change; correlating it to symptom relief almost never comes out clean. Mechanism is real but not the whole story. Ten more years needed.
62%
Congress will likely try to expand psychedelic access for veterans this fall
Within the next ten weeks, at least one member of Congress is expected to formally propose adding a provision to a major defense or veterans' affairs bill that would expand veterans' access to ibogaine (a powerful plant-based psychedelic) or other psychedelic therapies. This push is fueled by recent Stanford University research showing ibogaine may help veterans with opioid addiction and PTSD (post-traumatic stress disorder), and by renewed public attention to veterans' mental health. Getting it formally introduced is step one — passing is a much longer road.
→ Congress is likely to formally propose giving veterans easier access to ibogaine therapy within the next ten weeks, backed by new Stanford research.
Resolves: 2026-10-08 · Global
LEGISLATION
the precise call ▾
A veteran ibogaine/psychedelic access provision is formally introduced or offered as an NDAA/VA amendment within 10 weeks, citing Stanford ibogaine data.. Iran withdrawal creates a veteran-mental-health news peg. Stanford's ibogaine-opioid-PTSD work gives bipartisan cover. Cosponsors will move — that's how these windows work.